Abstract
Aims/hypothesis To investigate the joint effects of retinopathy and systemic vascular comorbidities on mortality.
Methods This study included 5703 participants (≥40 years old) from the 2005-2008 National Health and Nutrition Examination Survey. The Early Treatment Diabetic Retinopathy Study grading scale was used to evaluate the retinopathy status. Systemic vascular comorbidities included diabetes mellitus (DM), high blood pressure (HBP), chronic kidney disease (CKD) and cardiovascular disease (CVD). Time to death was calculated as the time from baseline to either the date of death or censoring (December 31st, 2015), whichever came first. Risks of mortality were estimated using Cox proportional hazards models.
Results After adjusting for confounders, the presence of retinopathy predicted higher all-cause mortality (hazard ratio [HR], 1.40; 95% confidence interval [CI], 1.09-1.81). The all-cause mortality among participants with both retinopathy and systemic vascular comorbidities including DM (HR, 1.63; 95% CI, 1.06-2.50), HBP (HR, 1.46; 95% CI, 1.03-2.08), CKD (HR, 1.71; 95% CI, 1.24-2.35) and CVD (HR, 1.88; 95% CI, 1.19-2.96) was significantly higher than that among those without either condition.
Conclusions/interpretation In this prospective study, individuals with retinopathy had increased all-cause mortality. The joint effects of retinopathy and major systemic vascular comorbidities increased the all-cause mortality further, suggesting that more extensive vascular risk factor assessment and management are needed to detect the burden of vascular pathologies and improve long-term survival in individuals with retinopathy.
What is already known about this subject?Retinopathy has been recognized as an independent risk factor for mortality.
What is the key question?What are the joint effects of retinopathy and systemic vascular comorbidities (including diabetes mellitus, hypertension and chronic kidney disease and cardiovascular disease) on mortality?
What are the new findings?Consistent evidence on the increased risk of mortality among individuals with retinopathy was noted in a large sample of middle-aged and older adults.
The co-occurrence of retinopathy and systemic vascular conditions (diabetes mellitus, hypertension and chronic kidney disease and cardiovascular disease) further increased all-cause mortality independent of other covariates.
How might this impact on clinical practice in the foreseeable future?Individuals with retinopathy may benefit from a comprehensive vascular assessment.
Intensive vascular risk reduction is needed in the management of patients with retinopathy and and micro- or macrovascular disorders.
Highlighted the importance of retinopathy screening using retinal imaging for identifying individuals at high risk of mortality, particularly among individuals with systemic vascular comorbidities.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
The present work was supported by the Fundamental Research Funds of the State Key Laboratory of Ophthalmology, Project of Investigation on Health Status of Employees in Financial Industry in Guangzhou, China (Z012014075), Science and Technology Program of Guangzhou, China (202002020049). Prof. Mingguang He receives support from the University of Melbourne at Research Accelerator Program and the CERA Foundation. The Centre for Eye Research Australia receives Operational Infrastructure Support from the Victorian State Government. The sponsor or funding organization had no role in the design or conduct of this research.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Access to the NHANES dataset was granted through registration. The application number for the present study is Protocol #2005-06. The National Center for Health Statistics (NCHS) research ethics review board reviewed and approved the NHANES protocols. The NHANES was conducted in accordance with the Declaration of Helsinki. All participants gave their written informed consent before being enrolled in the NHANES.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
The NHANES dataset used in this analysis were publicly available and de-identified, the present study received exemption from review by the institutional review board.
Abbreviations and Acronyms
- CVD
- cardiovascular disease
- NHANES
- National Health and Nutrition Examination Survey
- DM
- diabetes mellitus
- HBP
- high blood pressure
- CKD
- chronic kidney disease
- HR
- hazard ratios
- CI
- confidence interval
- ETDRS
- Early Treatment Diabetic Retinopathy Study
- NDI
- National Death Index
- NPR
- non-proliferative retinopathy
- PR
- proliferative retinopathy
- eGFR
- estimated glomerular filtration rate
- ICD
- International Classification of Diseases, Injuries and Causes of death
- BMI
- body mass index
- CRP
- C-reactive protein
- PIR
- poverty income ratio
- SE
- standard errors
- VIF
- variance inflation factors
- IQR
- interquartile range
